Cancer medication helps reduce SIV reservoir, increasing hope for HIV cure

Emory University researchers have provided the first proof of concept in a nonhuman primate model for eliminating HIV-infected cells with venetoclax, a clinically approved cancer medication. Venetoclax effectively targets and blocks Bcl-2, a protein that not only regulates whether cells live or die but also promotes the survival of cancer cells. Similarly, Bcl-2 is a culprit in sustaining HIV cell reservoirs.

Read it at Medical Xpress ↗

← Front page